ArticleClinical ophthalmology (Auckland, N.Z.)2019
Incidence and management of symptomatic dry eye related to LASIK for myopia, with topical cyclosporine A.
Article in Clinical ophthalmology (Auckland, N.Z.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 17 citations in OpenAlex.
- Ocular surface disease following LASIK and cataract surgery: a review of their interrelated complications.Frontiers in medicine · 2025Review
- Reduced Ocular Surface Inflammation in SMILE Patients: The Beneficial Outcome of 0.1% Ciclosporin Cationic Emulsion Treatment.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Study of corneal and retinal thicknesses at five years after FS-LASIK and SMILE for myopia.BMC ophthalmology · 2024Article
- Refractive surgery and dry eye - An update.Indian journal of ophthalmology · 2023Review
- Post-LASIK dry eye disease: A comprehensive review of management and current treatment options.Frontiers in medicine · 2023Review
- Ocular Neuropathic Pain: An Overview Focusing on Ocular Surface Pains.Clinical ophthalmology (Auckland, N.Z.) · 2020Review
- A Review of the Mechanism of Action of Cyclosporine A: The Role of Cyclosporine A in Dry Eye Disease and Recent Formulation Developments.Clinical ophthalmology (Auckland, N.Z.) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the incidence of transient dry eye associated with LASIK for myopia and the efficacy of topical cyclosporine A administration.
methodsGroup A was formed from 145 (82 female, 63 male) eyes that developed clinically significant dry eye within 1 month post-LASIK and were subjected to cyclosporine A treatment. A "non-symptomatic for dry eye" and age- and gender-matched group (group B) was formed from the same pool of patients to serve as control. Schirmer's, tear film break-up time (TBUT) and Ocular Surface Disease Index (OSDI) questionnaire were evaluated. Central corneal epithelial thickness (CET) and topographic epithelial thickness variability (TVT) were evaluated as quantitative dry eye objective markers. Subjective patient survey was also assessed.
resultsMean age was 39.7±6.2 years for the female and 47.67±9.5 years for the male patients, in group A. Schirmer's test mean preoperative value was 8.4±3.1 mm; and 4.5±3.6 mm at 1 month post-LASIK. Statistically significant decrease from 1 month post-LASIK baseline was found at 12 months (8.2±2.1 mm;
conclusionTopical cyclosporine A treatment is an effective alternative in the management of LASIK for myopia-related transient dry eye. Optical coherence tomography epithelial mapping may provide an objective benchmark in diagnosing and monitoring this significant disorder and its correlation with visual symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.